Aryl Hydrocarbon Receptor Treatments for PP

EP: 1.Overview of PP

EP: 2.The Role of Physician Assistants in PP Management

EP: 3.Factors to Consider when Treating PP

EP: 4.Impact of PP Comorbidities

EP: 5.Treatment Options for Pregnant People With PP

EP: 6.Caring for Pediatric Patients With PP

EP: 7.PP Treatment Selection: Best Practices

EP: 8.Drug Class Considerations for Patients With PP

EP: 9.PP Treatment Efficacy

EP: 10.Topical Therapy Options for PP

EP: 11.Plaque Psoriasis Treatment Selection Considerations

Now Viewing

EP: 12.Aryl Hydrocarbon Receptor Treatments for PP

EP: 13.Tapinarof Selectivity and Mechanism of Action for PP Treatment

EP: 14.Long-Term Efficacy and Safety Data on PP Treatments

EP: 15.Identifying the Remittive Effect in PP Patients

EP: 16.Positioning Aryl Hydrocarbon Receptor Agonists in PP Treatment Regimens

EP: 17.Key Takeaways for the Management of PP

EP: 18.Considering Plaque Psoriasis Comorbidities in Treatment Plans

Transcript

Lauren Miller, MPAS, PA-C: Speaking specifically about topical therapy, we have some newer therapeutic options and mechanisms of action. Two came out last year relatively close together. I’d be very surprised—because you see so many patients with psoriasis—if you don’t have experience with these. Let’s talk specifically about aryl hydrocarbon receptors. What are they, and how can they play into therapeutic options for patients with plaque psoriasis?

TJ Chao, MPAS, PA-C: Speaking specifically about tapinarof, I’ve had over 100 patients who I’ve prescribed that product to. I’ve seen it help drive improvements in the disease. If you look at the mechanism of action of tapinarof, essentially it binds to the aryl hydrocarbon receptor and drives through gene transcription normalcy of the cell. You’re trying to get it to homeostasis and not allow those pathogenic cytokines to occur, like T helper 17 releasing pathogenic IL-17 cytokines.

Lauren Miller, MPAS, PA-C: Specifically, it’s interesting that aryl hydrocarbon receptor is something we’ve never heard of before. That’s novel. In this instance, tapinarof specifically, is an agonist. That’s something that we haven’t heard of either. Everything else we have is inhibitory or a blocker. That’s a novelty, and that’s very important. It probably plays into its efficacy and its safety. But 1 of the interesting things about aryl hydrocarbon receptors is that they’re found throughout the body in different areas, not just the skin. It’s very ligand specific. Depending on what it binds to and where it is in the body is going to determine what the effect is. Specifically, we’re talking about the skin, but it’s interesting to note that it’s also in other areas of the body too.

Transcript edited for clarity.